Gel comprising tenofovir or tenofovir disoproxil

摘要

The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (NRTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenoforvir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections.